Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

ABEO | Abeona Therapeutics Inc

Index- P/E- EPS (ttm)-3.00 Insider Own9.49% Shs Outstand24.76M Perf Week11.08%
Market Cap104.24M Forward P/E- EPS next Y-1.77 Insider Trans-0.39% Shs Float22.41M Perf Month-3.00%
Income-36.37M PEG- EPS next Q-0.53 Inst Own40.44% Short Float / Ratio2.68% / 4.36 Perf Quarter4.47%
Sales3.57M P/S29.20 EPS this Y55.65% Inst Trans27.38% Short Interest0.60M Perf Half Y48.76%
Book/sh0.44 P/B9.68 EPS next Y27.83% ROA-74.02% Target Price21.50 Perf Year36.69%
Cash/sh1.50 P/C2.81 EPS next 5Y- ROE-247.16% 52W Range2.19 - 5.80 Perf YTD36.69%
Dividend- P/FCF- EPS past 5Y19.64% ROI-265.06% 52W High-27.41% Beta1.28
Dividend %- Quick Ratio4.67 Sales past 5Y7.06% Gross Margin-7.06% 52W Low92.24% ATR0.35
Employees57 Current Ratio4.67 Sales Q/Q250.00% Oper. Margin-1261.86% RSI (14)57.80 Volatility12.91% 8.56%
OptionableYes Debt/Eq0.64 EPS Q/Q35.30% Profit Margin-1019.37% Rel Volume2.68 Prev Close3.93
ShortableYes LT Debt/Eq0.47 EarningsAug 08 BMO Payout- Avg Volume137.88K Price4.21
Recom1.00 SMA205.14% SMA5013.35% SMA20029.27% Volume369,339 Change7.12%
Date Action Analyst Rating Change Price Target Change
Nov-11-20Upgrade Cantor Fitzgerald Neutral → Overweight $4
Sep-18-20Initiated B. Riley FBR Buy $5
Feb-10-20Initiated SVB Leerink Outperform $6
Dec-10-19Resumed Cantor Fitzgerald Neutral $2 → $4
Aug-15-19Downgrade Maxim Group Buy → Hold
Aug-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $29 → $2
Jul-26-19Downgrade Mizuho Buy → Neutral $17 → $4
Jun-27-19Initiated Mizuho Buy
Oct-12-18Initiated Mizuho Buy $17
Jun-05-18Initiated Seaport Global Securities Buy $29
Sep-26-23 07:30AM
Sep-12-23 12:48PM
Sep-07-23 07:30AM
Aug-30-23 07:30AM
07:41AM Loading…
Aug-11-23 07:41AM
Aug-08-23 08:27AM
Jul-28-23 07:30AM
Jul-19-23 08:30AM
Jul-07-23 08:30AM
Jul-03-23 08:45AM
Jun-09-23 07:30AM
Jun-01-23 07:30AM
May-30-23 08:00AM
12:27AM Loading…
May-25-23 12:27AM
May-22-23 07:30AM
May-16-23 09:00AM
May-13-23 08:15AM
May-11-23 07:54AM
Apr-18-23 07:15AM
Apr-10-23 07:30AM
Mar-31-23 06:22AM
Mar-29-23 07:30AM
Mar-24-23 07:30AM
Mar-16-23 07:30AM
Mar-14-23 07:30AM
Nov-14-22 07:30AM
02:28PM Loading…
Nov-08-22 02:28PM
Nov-03-22 12:44PM
Oct-19-22 07:30AM
Oct-04-22 07:30AM
Sep-22-22 07:30AM
Sep-13-22 07:30AM
Sep-08-22 08:48AM
Aug-11-22 07:30AM
Jul-20-22 07:30AM
Jun-24-22 10:08AM
Jun-13-22 01:27PM
Jun-10-22 03:30PM
Jun-08-22 01:21PM
Jun-06-22 02:04PM
Jun-01-22 02:25PM
May-31-22 02:27PM
May-25-22 02:29PM
May-23-22 03:32PM
May-19-22 03:02PM
May-18-22 03:12PM
May-17-22 09:27AM
May-13-22 07:30AM
May-12-22 02:47PM
May-11-22 02:28PM
May-10-22 02:36PM
May-06-22 03:48PM
May-04-22 07:30AM
May-03-22 07:00AM
Apr-29-22 09:00AM
Apr-19-22 10:51AM
Mar-31-22 07:30AM
Mar-28-22 11:20AM
Mar-14-22 07:30AM
Jan-25-22 10:00AM
Dec-22-21 07:30AM
Dec-17-21 09:00AM
Dec-16-21 04:01PM
Dec-02-21 07:25AM
Nov-19-21 10:00AM
Nov-18-21 07:30AM
Nov-17-21 07:30AM
Nov-16-21 07:30AM
Nov-15-21 07:45AM
Oct-21-21 07:30AM
Oct-13-21 07:30AM
Oct-12-21 07:30AM
Sep-21-21 04:01PM
Sep-07-21 07:30AM
Aug-10-21 07:30AM
Jul-28-21 04:01PM
Jul-26-21 07:30AM
Jul-23-21 07:30AM
Jul-07-21 12:02PM
Jun-14-21 10:00AM
Jun-02-21 07:30AM
May-26-21 07:30AM
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seshadri VishwasChief Executive OfficerSep 27Buy4.0720,00081,400521,731Sep 29 07:30 AM
Charles Faith L.DirectorSep 27Sale4.918,33040,92470,773Sep 29 04:30 PM
Alland LeilaDirectorSep 27Sale3.907,24628,27071,857Sep 29 04:30 PM
Alvino MarkDirectorSep 27Sale3.916,31624,72469,900Sep 29 04:30 PM
Silverstein Christine BerniDirectorSep 27Sale3.916,33024,72187,884Sep 29 04:30 PM
Amoroso MichaelDirectorSep 27Sale3.915,50821,542108,957Sep 29 04:30 PM
Amoroso MichaelDirectorSep 20Sale3.903271,275114,465Sep 22 04:05 PM
Vazzano Joseph WalterChief Financial OfficerSep 19Buy3.823,00011,458238,179Sep 20 09:00 AM
O'Malley Brendan M.SVP, General CounselSep 18Buy3.803,00011,400187,421Sep 19 09:00 AM
Amoroso MichaelDirectorJun 20Sale4.453381,504114,792Jun 21 04:05 PM
Alvino MarkDirectorApr 25Sale3.258872,88317,527May 05 04:05 PM
Amoroso MichaelDirectorMar 20Sale2.3326862456,441Mar 21 05:13 PM
Amoroso MichaelDirectorMar 03Sale2.381,0022,38556,709Mar 03 07:06 PM
O'Malley Brendan M.SVP, General CounselDec 09Buy3.135,86918,37093,830Dec 12 04:10 PM
O'Malley Brendan M.SVP, General CounselNov 18Buy3.997,50029,92587,961Nov 21 09:00 AM
Vazzano Joseph WalterChief Financial OfficerNov 18Buy4.002,50010,00095,250Nov 21 09:00 AM